No Cover Image

Journal article 334 views 71 downloads

Angiogenesis inhibitor therapies for advanced renal cell carcinoma: Toxicity and treatment patterns in clinical practice from a global medical chart review

WILLIAM K. OH, DAVID McDERMOTT, CAMILLO PORTA, ANTONIN LEVY, REZA ELAIDI, FLORIAN SCOTTE, ROBERT HAWKINS, DANIEL CASTELLANO, JOAQUIM BELLMUNT, SUN YOUNG RHA, JONG-MU SUN, PAUL NATHAN, BRUCE A. FEINBERG, JEFFREY SCOTT, RAY McDERMOTT, JIN-HEE AHN, John Wagstaff, YEN-HWA CHANG, YEN-CHUAN OU, PAUL DONNELLAN, CHAO-YUAN HUANG, JOHN McCAFFREY, PO-HUI CHIANG, CHENG-KENG CHUANG, CAROLINE KORVES, MAUREEN P. NEARY, JOSE R. DIAZ, FAISAL MEHMUD, MEI SHENG DUH

International Journal of Oncology, Volume: 44, Issue: 1, Pages: 5 - 16

Swansea University Author: John Wagstaff

  • 57729.pdf

    PDF | Version of Record

    © Oh et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY_NC 3.0].

    Download (311.06KB)

Check full text

DOI (Published version): 10.3892/ijo.2013.2181

Abstract

The aim of this study was to assess the treatment patterns and safety of sunitinib, sorafenib and bevacizumab in real-world clinical settings in US, Europe and Asia. Medical records were abstracted at 18 community oncology clinics in the US and at 21 tertiary oncology centers in US, Europe and Asia...

Full description

Published in: International Journal of Oncology
ISSN: 1019-6439 1791-2423
Published: Spandidos Publications 2013
Online Access: Check full text

URI: https://cronfa.swan.ac.uk/Record/cronfa57729
Tags: Add Tag
No Tags, Be the first to tag this record!
first_indexed 2021-09-15T14:21:55Z
last_indexed 2021-09-16T03:22:15Z
id cronfa57729
recordtype SURis
fullrecord <?xml version="1.0"?><rfc1807><datestamp>2021-09-15T15:23:53.2945505</datestamp><bib-version>v2</bib-version><id>57729</id><entry>2021-08-31</entry><title>Angiogenesis inhibitor therapies for advanced renal cell carcinoma: Toxicity and treatment patterns in clinical practice from a global medical chart review</title><swanseaauthors><author><sid>fdab5e9e2fe06c93d3ffa19c816bdcf6</sid><firstname>John</firstname><surname>Wagstaff</surname><name>John Wagstaff</name><active>true</active><ethesisStudent>false</ethesisStudent></author></swanseaauthors><date>2021-08-31</date><deptcode>SGMED</deptcode><abstract>The aim of this study was to assess the treatment patterns and safety of sunitinib, sorafenib and bevacizumab in real-world clinical settings in US, Europe and Asia. Medical records were abstracted at 18 community oncology clinics in the US and at 21 tertiary oncology centers in US, Europe and Asia for 883 patients &#x2265;18 years who had histologically/cytologically confirmed diagnosis of advanced RCC and received sunitinib (n=631), sorafenib (n=207) or bevacizumab (n=45) as first&#x2011;line treatment. No prior treatment was permitted. Data were collected on all adverse events (AEs) and treatment modifications, including discontinuation, interruption and dose reduction. Treatment duration was estimated using Kaplan-Meier analysis. Demographics were similar across treatment groups and regions. Median treatment duration ranged from 6.1 to 10.7 months, 5.1 to 8.5 months and 7.5 to 9.8 months for sunitinib, sorafenib and bevacizumab patients, respectively. Grade 3/4 AEs were experienced by 26.0, 28.0 and 15.6% of sunitinib, sorafenib and bevacizumab patients, respectively. Treatment discontinuations occurred in 62.4 (Asia) to 63.1% (US) sunitinib, 68.8 (Asia) to 90.0% (Europe) sorafenib, and 66.7 (Asia) to 81.8% (US) bevacizumab patients. Globally, treatment modifications due to AEs occurred in 55.1, 54.2 and 50.0% sunitinib, sorafenib and bevacizumab patients, respectively. This study in a large, global cohort of advanced RCC patients found that angiogenesis inhibitors are associated with high rates of AEs and treatment modifications. Findings suggest an unmet need for more tolerable agents for RCC treatment.</abstract><type>Journal Article</type><journal>International Journal of Oncology</journal><volume>44</volume><journalNumber>1</journalNumber><paginationStart>5</paginationStart><paginationEnd>16</paginationEnd><publisher>Spandidos Publications</publisher><placeOfPublication/><isbnPrint/><isbnElectronic/><issnPrint>1019-6439</issnPrint><issnElectronic>1791-2423</issnElectronic><keywords>renal cell carcinoma, angiogenesis inhibitors, safety, treatment patterns, interruption, dose reduction</keywords><publishedDay>15</publishedDay><publishedMonth>11</publishedMonth><publishedYear>2013</publishedYear><publishedDate>2013-11-15</publishedDate><doi>10.3892/ijo.2013.2181</doi><url/><notes/><college>COLLEGE NANME</college><department>Medical School - School</department><CollegeCode>COLLEGE CODE</CollegeCode><DepartmentCode>SGMED</DepartmentCode><institution>Swansea University</institution><apcterm/><lastEdited>2021-09-15T15:23:53.2945505</lastEdited><Created>2021-08-31T12:47:18.8104924</Created><path><level id="1">Faculty of Medicine, Health and Life Sciences</level><level id="2">Swansea University Medical School - Medicine</level></path><authors><author><firstname>WILLIAM K.</firstname><surname>OH</surname><order>1</order></author><author><firstname>DAVID</firstname><surname>McDERMOTT</surname><order>2</order></author><author><firstname>CAMILLO</firstname><surname>PORTA</surname><order>3</order></author><author><firstname>ANTONIN</firstname><surname>LEVY</surname><order>4</order></author><author><firstname>REZA</firstname><surname>ELAIDI</surname><order>5</order></author><author><firstname>FLORIAN</firstname><surname>SCOTTE</surname><order>6</order></author><author><firstname>ROBERT</firstname><surname>HAWKINS</surname><order>7</order></author><author><firstname>DANIEL</firstname><surname>CASTELLANO</surname><order>8</order></author><author><firstname>JOAQUIM</firstname><surname>BELLMUNT</surname><order>9</order></author><author><firstname>SUN YOUNG</firstname><surname>RHA</surname><order>10</order></author><author><firstname>JONG-MU</firstname><surname>SUN</surname><order>11</order></author><author><firstname>PAUL</firstname><surname>NATHAN</surname><order>12</order></author><author><firstname>BRUCE A.</firstname><surname>FEINBERG</surname><order>13</order></author><author><firstname>JEFFREY</firstname><surname>SCOTT</surname><order>14</order></author><author><firstname>RAY</firstname><surname>McDERMOTT</surname><order>15</order></author><author><firstname>JIN-HEE</firstname><surname>AHN</surname><order>16</order></author><author><firstname>John</firstname><surname>Wagstaff</surname><order>17</order></author><author><firstname>YEN-HWA</firstname><surname>CHANG</surname><order>18</order></author><author><firstname>YEN-CHUAN</firstname><surname>OU</surname><order>19</order></author><author><firstname>PAUL</firstname><surname>DONNELLAN</surname><order>20</order></author><author><firstname>CHAO-YUAN</firstname><surname>HUANG</surname><order>21</order></author><author><firstname>JOHN</firstname><surname>McCAFFREY</surname><order>22</order></author><author><firstname>PO-HUI</firstname><surname>CHIANG</surname><order>23</order></author><author><firstname>CHENG-KENG</firstname><surname>CHUANG</surname><order>24</order></author><author><firstname>CAROLINE</firstname><surname>KORVES</surname><order>25</order></author><author><firstname>MAUREEN P.</firstname><surname>NEARY</surname><order>26</order></author><author><firstname>JOSE R.</firstname><surname>DIAZ</surname><order>27</order></author><author><firstname>FAISAL</firstname><surname>MEHMUD</surname><order>28</order></author><author><firstname>MEI SHENG</firstname><surname>DUH</surname><order>29</order></author></authors><documents><document><filename>57729__20853__d3f6b412b46749cba5fc28136bc6dd43.pdf</filename><originalFilename>57729.pdf</originalFilename><uploaded>2021-09-15T15:22:17.8315876</uploaded><type>Output</type><contentLength>318529</contentLength><contentType>application/pdf</contentType><version>Version of Record</version><cronfaStatus>true</cronfaStatus><documentNotes>&#xA9; Oh et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY_NC 3.0].</documentNotes><copyrightCorrect>true</copyrightCorrect><language>eng</language><licence>https://creativecommons.org/licenses/by-nc/3.0/</licence></document></documents><OutputDurs/></rfc1807>
spelling 2021-09-15T15:23:53.2945505 v2 57729 2021-08-31 Angiogenesis inhibitor therapies for advanced renal cell carcinoma: Toxicity and treatment patterns in clinical practice from a global medical chart review fdab5e9e2fe06c93d3ffa19c816bdcf6 John Wagstaff John Wagstaff true false 2021-08-31 SGMED The aim of this study was to assess the treatment patterns and safety of sunitinib, sorafenib and bevacizumab in real-world clinical settings in US, Europe and Asia. Medical records were abstracted at 18 community oncology clinics in the US and at 21 tertiary oncology centers in US, Europe and Asia for 883 patients ≥18 years who had histologically/cytologically confirmed diagnosis of advanced RCC and received sunitinib (n=631), sorafenib (n=207) or bevacizumab (n=45) as first‑line treatment. No prior treatment was permitted. Data were collected on all adverse events (AEs) and treatment modifications, including discontinuation, interruption and dose reduction. Treatment duration was estimated using Kaplan-Meier analysis. Demographics were similar across treatment groups and regions. Median treatment duration ranged from 6.1 to 10.7 months, 5.1 to 8.5 months and 7.5 to 9.8 months for sunitinib, sorafenib and bevacizumab patients, respectively. Grade 3/4 AEs were experienced by 26.0, 28.0 and 15.6% of sunitinib, sorafenib and bevacizumab patients, respectively. Treatment discontinuations occurred in 62.4 (Asia) to 63.1% (US) sunitinib, 68.8 (Asia) to 90.0% (Europe) sorafenib, and 66.7 (Asia) to 81.8% (US) bevacizumab patients. Globally, treatment modifications due to AEs occurred in 55.1, 54.2 and 50.0% sunitinib, sorafenib and bevacizumab patients, respectively. This study in a large, global cohort of advanced RCC patients found that angiogenesis inhibitors are associated with high rates of AEs and treatment modifications. Findings suggest an unmet need for more tolerable agents for RCC treatment. Journal Article International Journal of Oncology 44 1 5 16 Spandidos Publications 1019-6439 1791-2423 renal cell carcinoma, angiogenesis inhibitors, safety, treatment patterns, interruption, dose reduction 15 11 2013 2013-11-15 10.3892/ijo.2013.2181 COLLEGE NANME Medical School - School COLLEGE CODE SGMED Swansea University 2021-09-15T15:23:53.2945505 2021-08-31T12:47:18.8104924 Faculty of Medicine, Health and Life Sciences Swansea University Medical School - Medicine WILLIAM K. OH 1 DAVID McDERMOTT 2 CAMILLO PORTA 3 ANTONIN LEVY 4 REZA ELAIDI 5 FLORIAN SCOTTE 6 ROBERT HAWKINS 7 DANIEL CASTELLANO 8 JOAQUIM BELLMUNT 9 SUN YOUNG RHA 10 JONG-MU SUN 11 PAUL NATHAN 12 BRUCE A. FEINBERG 13 JEFFREY SCOTT 14 RAY McDERMOTT 15 JIN-HEE AHN 16 John Wagstaff 17 YEN-HWA CHANG 18 YEN-CHUAN OU 19 PAUL DONNELLAN 20 CHAO-YUAN HUANG 21 JOHN McCAFFREY 22 PO-HUI CHIANG 23 CHENG-KENG CHUANG 24 CAROLINE KORVES 25 MAUREEN P. NEARY 26 JOSE R. DIAZ 27 FAISAL MEHMUD 28 MEI SHENG DUH 29 57729__20853__d3f6b412b46749cba5fc28136bc6dd43.pdf 57729.pdf 2021-09-15T15:22:17.8315876 Output 318529 application/pdf Version of Record true © Oh et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY_NC 3.0]. true eng https://creativecommons.org/licenses/by-nc/3.0/
title Angiogenesis inhibitor therapies for advanced renal cell carcinoma: Toxicity and treatment patterns in clinical practice from a global medical chart review
spellingShingle Angiogenesis inhibitor therapies for advanced renal cell carcinoma: Toxicity and treatment patterns in clinical practice from a global medical chart review
John Wagstaff
title_short Angiogenesis inhibitor therapies for advanced renal cell carcinoma: Toxicity and treatment patterns in clinical practice from a global medical chart review
title_full Angiogenesis inhibitor therapies for advanced renal cell carcinoma: Toxicity and treatment patterns in clinical practice from a global medical chart review
title_fullStr Angiogenesis inhibitor therapies for advanced renal cell carcinoma: Toxicity and treatment patterns in clinical practice from a global medical chart review
title_full_unstemmed Angiogenesis inhibitor therapies for advanced renal cell carcinoma: Toxicity and treatment patterns in clinical practice from a global medical chart review
title_sort Angiogenesis inhibitor therapies for advanced renal cell carcinoma: Toxicity and treatment patterns in clinical practice from a global medical chart review
author_id_str_mv fdab5e9e2fe06c93d3ffa19c816bdcf6
author_id_fullname_str_mv fdab5e9e2fe06c93d3ffa19c816bdcf6_***_John Wagstaff
author John Wagstaff
author2 WILLIAM K. OH
DAVID McDERMOTT
CAMILLO PORTA
ANTONIN LEVY
REZA ELAIDI
FLORIAN SCOTTE
ROBERT HAWKINS
DANIEL CASTELLANO
JOAQUIM BELLMUNT
SUN YOUNG RHA
JONG-MU SUN
PAUL NATHAN
BRUCE A. FEINBERG
JEFFREY SCOTT
RAY McDERMOTT
JIN-HEE AHN
John Wagstaff
YEN-HWA CHANG
YEN-CHUAN OU
PAUL DONNELLAN
CHAO-YUAN HUANG
JOHN McCAFFREY
PO-HUI CHIANG
CHENG-KENG CHUANG
CAROLINE KORVES
MAUREEN P. NEARY
JOSE R. DIAZ
FAISAL MEHMUD
MEI SHENG DUH
format Journal article
container_title International Journal of Oncology
container_volume 44
container_issue 1
container_start_page 5
publishDate 2013
institution Swansea University
issn 1019-6439
1791-2423
doi_str_mv 10.3892/ijo.2013.2181
publisher Spandidos Publications
college_str Faculty of Medicine, Health and Life Sciences
hierarchytype
hierarchy_top_id facultyofmedicinehealthandlifesciences
hierarchy_top_title Faculty of Medicine, Health and Life Sciences
hierarchy_parent_id facultyofmedicinehealthandlifesciences
hierarchy_parent_title Faculty of Medicine, Health and Life Sciences
department_str Swansea University Medical School - Medicine{{{_:::_}}}Faculty of Medicine, Health and Life Sciences{{{_:::_}}}Swansea University Medical School - Medicine
document_store_str 1
active_str 0
description The aim of this study was to assess the treatment patterns and safety of sunitinib, sorafenib and bevacizumab in real-world clinical settings in US, Europe and Asia. Medical records were abstracted at 18 community oncology clinics in the US and at 21 tertiary oncology centers in US, Europe and Asia for 883 patients ≥18 years who had histologically/cytologically confirmed diagnosis of advanced RCC and received sunitinib (n=631), sorafenib (n=207) or bevacizumab (n=45) as first‑line treatment. No prior treatment was permitted. Data were collected on all adverse events (AEs) and treatment modifications, including discontinuation, interruption and dose reduction. Treatment duration was estimated using Kaplan-Meier analysis. Demographics were similar across treatment groups and regions. Median treatment duration ranged from 6.1 to 10.7 months, 5.1 to 8.5 months and 7.5 to 9.8 months for sunitinib, sorafenib and bevacizumab patients, respectively. Grade 3/4 AEs were experienced by 26.0, 28.0 and 15.6% of sunitinib, sorafenib and bevacizumab patients, respectively. Treatment discontinuations occurred in 62.4 (Asia) to 63.1% (US) sunitinib, 68.8 (Asia) to 90.0% (Europe) sorafenib, and 66.7 (Asia) to 81.8% (US) bevacizumab patients. Globally, treatment modifications due to AEs occurred in 55.1, 54.2 and 50.0% sunitinib, sorafenib and bevacizumab patients, respectively. This study in a large, global cohort of advanced RCC patients found that angiogenesis inhibitors are associated with high rates of AEs and treatment modifications. Findings suggest an unmet need for more tolerable agents for RCC treatment.
published_date 2013-11-15T04:13:41Z
_version_ 1763753927489093632
score 11.013148

Similar Items